试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-02
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
编号:NCT01163201登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:Treg cells、CD3+ Teff cells、Fludarabine、Cyclophosphamide
登记的停止原因(原文):Replaced by a new study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-02
A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain
编号:NCT01190722登记状态:入组前撤回企业 / 申办者:Karolinska Institutet
药物 / 成分:etoricoxib、Diclofenac
登记的停止原因(原文):The study site was closed down
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-02
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
编号:NCT01639456登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:CD3-/CD19- natural killer cells、CD3-CD56+ natural killer cells、CliniMACS® CD3 and CD19 Reagent System、CliniMACS® CD56 Reagent System
登记的停止原因(原文):study was abandoned and a new study was written to replace this one
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-02
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
编号:NCT01677949登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:Clofarabine、Etoposide、Cyclophosphamide、allogeneic hematopoietic cell transplantation
登记的停止原因(原文):Slow accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-02
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
编号:NCT02118311登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:T Regulatory cells、Fludarabine、Cyclophosphamide、Total Body Irradiation
登记的停止原因(原文):Changing study design. Will replace with a different protocol.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-02
MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)
编号:NCT02410239登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:Mesenchymal Stem Cells
登记的停止原因(原文):Research cancelled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-12-02
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
编号:NCT02947334登记状态:入组前撤回企业 / 申办者:Pfizer
药物 / 成分:Bococizumab、Placebo
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
编号:NCT00983944登记状态:入组前撤回企业 / 申办者:Ohio State University Comprehensive Cancer Center
药物 / 成分:bleomycin sulfate、rituximab、EPOCH regimen、cyclophosphamide
登记的停止原因(原文):Inadequate Accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-30
Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
编号:NCT02947113登记状态:入组前撤回企业 / 申办者:The Netherlands Cancer Institute
药物 / 成分:Cisplatin、hypofractionated radiotherapy、Pemetrexed、Etoposide
登记的停止原因(原文):New studies available with immunotherapy so recruitment is no longer acceptable.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-11-29
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
编号:NCT00005998登记状态:入组前撤回企业 / 申办者:Masonic Cancer Center, University of Minnesota
药物 / 成分:carmustine、cyclophosphamide、cytarabine、dexamethasone
登记的停止原因(原文):Withdrawn because study never enrolled patients
查看官方原始记录 ↗